Assisted Reproductive Technology (ART) Market Size, Share, Growth, and Industry Analysis, By Type (In-Vitro Fertilization, Artificial Insemination, Others), By Application (Hospitals, Fertility Clinics, Others), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET OVERVIEW

The global Assisted Reproductive Technology (ART) Market size estimated at USD 25.33 billion in 2026 and is projected to reach USD 47.16 billion by 2035, growing at a CAGR of 7.15% from 2026 to 2035.

The Assisted Reproductive Technology (ART) Market continues to expand because infertility affects nearly 17% of the global adult population, representing approximately 1 in 6 people. More than 3 million ART cycles are performed worldwide every year, resulting in over 500,000 live births annually. In-vitro fertilization (IVF) accounts for more than 82% of all ART procedures, while frozen embryo transfer represents approximately 44% of embryo transfer cycles in advanced fertility centers. More than 8 million babies have been born through IVF since the first successful procedure in 1978. Increasing maternal age, rising infertility among men, improved embryo culture systems, and wider access to fertility preservation services continue to strengthen the Assisted Reproductive Technology (ART) Market across developed and emerging healthcare systems.

The United States represents one of the largest Assisted Reproductive Technology (ART) Market destinations, with more than 460 fertility clinics operating nationwide and over 390,000 ART cycles conducted annually. Approximately 2.4% of all infants born in the country are conceived through ART procedures. Women aged 35 years and older account for more than 56% of IVF treatment cycles, while frozen embryo transfers exceed 75% of embryo transfer procedures in many specialized centers. More than 98% of fertility clinics utilize advanced embryo incubation technologies, and genetic embryo screening is performed in nearly 44% of IVF cycles, supporting higher implantation success and improved clinical outcomes.

KEY FINDINGS

LATEST TRENDS

The Assisted Reproductive Technology (ART) Market is witnessing rapid technological advancement through artificial intelligence, embryo imaging, cryopreservation improvements, and genetic screening. More than 44% of embryo transfer procedures now involve frozen embryos because they provide greater scheduling flexibility and improved endometrial preparation. Time-lapse embryo monitoring systems have been adopted by nearly 35% of advanced fertility laboratories, enabling continuous embryo assessment without disturbing incubation conditions. Preimplantation genetic testing is utilized in approximately 39% of IVF cycles involving older maternal age or hereditary disease screening.

Fertility preservation has become another major trend within the Assisted Reproductive Technology (ART) Market. Egg freezing procedures have increased significantly among women aged 30 to 38 years, while sperm cryopreservation demand has expanded among oncology patients before chemotherapy. More than 80% of fertility laboratories now use vitrification rather than conventional slow freezing because survival rates after thawing exceed 90% in many clinical settings. Digital patient management systems are also improving operational efficiency, with nearly 58% of fertility centers integrating electronic treatment tracking and laboratory management software.

MARKET DYNAMICS

Driver

Rising infertility prevalence and delayed parenthood.

Growing infertility remains the strongest growth driver for the Assisted Reproductive Technology (ART) Market. Global health estimates indicate infertility affects approximately 17% of adults. Female age at first childbirth continues to increase in numerous developed economies, with average maternal age exceeding 30 years in several countries. Male infertility contributes to nearly 50% of infertility cases, increasing demand for advanced reproductive procedures. More than 3 million ART cycles are conducted annually worldwide, while over 500,000 births result from these treatments every year.

Restraint

High treatment costs and limited reimbursement coverage.

Despite technological progress, affordability remains a major limitation in the Assisted Reproductive Technology (ART) Market. Approximately 61% of patients require more than one IVF cycle before achieving pregnancy, increasing overall treatment expenses. Insurance reimbursement remains limited across numerous healthcare systems, with partial coverage available in only selected regions. Nearly 48% of prospective patients postpone treatment because of financial concerns, while around 36% discontinue therapy before completing recommended treatment cycles.

Expansion of fertility preservation and genetic technologies

Opportunity

Fertility preservation presents significant opportunities within the Assisted Reproductive Technology (ART) Market. Increasing awareness among cancer patients, career-oriented women, and individuals seeking delayed parenthood has accelerated demand for egg and sperm freezing services.

Vitrification success rates now exceed 90% for many clinical applications, encouraging broader acceptance of cryopreservation. Preimplantation genetic testing is expanding rapidly, helping identify chromosomal abnormalities before embryo transfer. AI-assisted embryo selection systems reduce subjectivity and improve laboratory workflow.

Ethical regulations and shortage of skilled embryologists

Challenge

Regulatory diversity remains one of the most significant challenges for the Assisted Reproductive Technology (ART) Market. Countries maintain different legal frameworks regarding embryo storage, donor programs, surrogacy, and genetic testing, creating operational complexity for multinational providers.

Nearly 41% of fertility centers report difficulties recruiting experienced embryologists due to specialized training requirements. Maintaining laboratory quality standards demands continuous monitoring of temperature, air filtration, humidity, and culture conditions.

•   
•   
  

  Download Free Sample to learn more about this report

    

ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET SEGMENTATION

By Type

• In-Vitro Fertilization: In-Vitro Fertilization (IVF) is the largest segment of the Assisted Reproductive Technology (ART) Market, accounting for approximately 72% of all ART procedures performed globally. More than 3 million IVF cycles are initiated every year, contributing to over 500,000 births annually. IVF is the preferred treatment for tubal infertility, severe male infertility, endometriosis, and unexplained infertility. Intracytoplasmic sperm injection (ICSI) is incorporated into nearly 68% of IVF cycles to improve fertilization outcomes, particularly in male-factor infertility cases.

• Artificial Insemination: Artificial Insemination represents approximately 19% of the Assisted Reproductive Technology (ART) Market and remains an important first-line fertility treatment for selected infertility conditions. Intrauterine insemination (IUI) is the most frequently performed procedure within this category because it is less invasive and requires fewer laboratory interventions than IVF. Clinical pregnancy success rates generally range between 10% and 20% per treatment cycle depending on maternal age and infertility diagnosis.

• Others: The "Others" segment contributes approximately 9% of the Assisted Reproductive Technology (ART) Market and includes gamete intrafallopian transfer, zygote intrafallopian transfer, fertility preservation procedures, donor egg programs, donor embryo services, and emerging reproductive technologies. Fertility preservation has become one of the fastest-growing clinical services, particularly among oncology patients, with more than 80% of major cancer centers recommending reproductive counseling before chemotherapy.

By Application

• Hospitals: Hospitals account for approximately 26% of the Assisted Reproductive Technology (ART) Market because they provide comprehensive reproductive healthcare alongside obstetrics, gynecology, oncology, and maternal medicine. Large tertiary hospitals frequently operate multidisciplinary fertility departments equipped with embryology laboratories, operating theaters, diagnostic imaging units, and genetic counseling services. More than 70% of university teaching hospitals in developed healthcare systems provide advanced reproductive medicine services.

• Fertility Clinics: Fertility clinics dominate the Assisted Reproductive Technology (ART) Market with approximately 67% market share because they specialize exclusively in infertility diagnosis and reproductive treatment. More than 460 fertility clinics operate across the United States alone, while thousands of specialized centers serve patients worldwide. These facilities maintain highly controlled embryology laboratories equipped with incubators, micromanipulators, cryogenic storage systems, and time-lapse imaging technologies.

• Others: Other healthcare facilities account for approximately 7% of the Assisted Reproductive Technology (ART) Market and include ambulatory reproductive centers, academic research institutes, specialized women's health centers, and collaborative reproductive laboratories. These facilities support fertility assessment, reproductive endocrinology consultations, fertility preservation, donor programs, and follow-up care. Academic institutions contribute significantly to reproductive medicine research, conducting studies on embryo development, laboratory technologies, reproductive genetics, and fertility preservation methods.

•   
•   
  Download Free Sample to learn more about this report

    

ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET REGIONAL INSIGHTS

• North America

North America accounts for 37% of the global assisted reproductive technology (ART) market, supported by advanced fertility clinics, high healthcare spending, and strong adoption of in-vitro fertilization (IVF), egg freezing, and other fertility treatment procedures. The United States represents the largest contributor due to the presence of specialized reproductive healthcare centers, increasing infertility awareness, and growing demand for advanced fertility solutions. Canada also contributes through expanding fertility services and supportive healthcare infrastructure. Rising maternal age, delayed family planning, and increasing acceptance of assisted reproduction procedures are driving demand for ART services across the region.

• Europe

Europe represents 30% of the global assisted reproductive technology (ART) market, driven by established fertility care systems, increasing infertility treatments, and strong medical research capabilities. Countries such as Germany, France, the United Kingdom, Spain, and Italy are major contributors due to their advanced reproductive healthcare facilities and growing accessibility of fertility treatments. The region has witnessed increasing adoption of IVF, intracytoplasmic sperm injection (ICSI), and fertility preservation techniques. Supportive healthcare policies, rising awareness regarding reproductive health, and improvements in embryo selection technologies are contributing to market growth across European countries.

• Asia-Pacific

Asia-Pacific holds 24% of the global assisted reproductive technology (ART) market, supported by increasing infertility rates, expanding healthcare infrastructure, and rising awareness of fertility treatment options. China, India, Japan, South Korea, and Australia are key contributors due to growing investments in fertility clinics and reproductive healthcare services. India and China are witnessing higher demand due to large patient populations and increasing acceptance of assisted reproduction procedures. Growing medical tourism, improved access to fertility specialists, and advancements in reproductive technologies are further supporting ART adoption across the region.

• Middle East & Africa

Middle East & Africa contributes 6% of the global assisted reproductive technology (ART) market, with growth supported by improving healthcare facilities, rising fertility awareness, and increasing availability of specialized reproductive services. Gulf countries such as the United Arab Emirates, Saudi Arabia, and Qatar are major contributors due to investments in advanced fertility centers and medical infrastructure. African markets are gradually developing through improved healthcare access and growing awareness of infertility treatments. Increasing demand for IVF procedures, reproductive counseling, and fertility preservation services is creating new opportunities across the region.

• Rest of World

Rest of World represents 3% of the global assisted reproductive technology (ART) market, with Latin America accounting for a significant portion of regional demand. Countries such as Brazil, Mexico, and Argentina are key markets due to expanding fertility clinics, rising healthcare investments, and increasing acceptance of assisted reproduction methods. Growing awareness about infertility solutions and improving access to reproductive specialists are supporting market development. The expansion of private healthcare services and increasing availability of advanced fertility treatments are expected to create additional opportunities for ART providers across emerging markets.

KEY INDUSTRY PLAYERS

The global Assisted Reproductive Technology (ART) Market consists of leading fertility healthcare providers, reproductive technology companies, and medical device manufacturers focused on improving fertility treatment, IVF procedures, embryo assessment, and cryopreservation. Companies such as CooperSurgical, Vitrolife, Merck KGaA, Ferring Pharmaceuticals, and Cook Medical are strengthening their market presence through advanced fertility equipment, laboratory technologies, reproductive medicines, and embryo monitoring solutions. Thermo Fisher Scientific, Hamilton Thorne, Esco Micro, Genea Biomedx, and FUJIFILM Irvine Scientific are developing innovative solutions that improve laboratory automation, embryo selection, culture conditions, and reproductive treatment outcomes.

ART providers and technology manufacturers are investing in AI-powered embryo assessment, digital monitoring, automated laboratory systems, cryopreservation technologies, and advanced reproductive diagnostics. The competitive landscape is driven by rising infertility rates, increasing IVF adoption, technological advancements, growing fertility awareness, and expanding demand for effective assisted conception solutions across global markets.

LIST OF TOP ASSISTED REPRODUCTIVE TECHNOLOGY (ART) COMPANIES

• Bloom IVF Centre
• CooperSurgical Inc.
• Ferring B.V.
• Hamilton Thorne
• Irvine Scientific
• Laboratoire CCD
• Microm Ltd.
• Nidacon International AB
• OvaScience
• Vitrolife

List Of Top 2 Companies Market Share

• CooperSurgical Inc. – Approximately 19% market share, supported by its extensive portfolio of IVF laboratory products, genetic testing solutions, embryo culture media, micromanipulation systems, and global distribution across more than 100 countries.

• Vitrolife – Approximately 16% market share, driven by strong demand for embryo culture media, cryopreservation solutions, time-lapse imaging systems, reproductive genetics products, and partnerships with fertility clinics across Europe, North America, and Asia-Pacific.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Assisted Reproductive Technology (ART) Market continues to attract substantial investment due to increasing infertility prevalence, technological innovation, and expanding fertility clinic infrastructure. More than 3 million ART treatment cycles are performed worldwide every year, creating sustained demand for laboratory equipment, embryo culture media, genetic testing solutions, cryogenic storage systems, and fertility software platforms. Approximately 58% of fertility clinics have invested in digital laboratory management systems to improve workflow efficiency and treatment accuracy. Investments in artificial intelligence have accelerated, with AI-assisted embryo grading reducing manual variability and supporting better embryo selection.

Fertility preservation services also present significant opportunities as egg freezing procedures continue increasing among women delaying childbirth and oncology patients preserving reproductive potential before treatment. Emerging economies are witnessing rapid expansion of specialized fertility clinics supported by improving healthcare infrastructure and growing public awareness. Strategic partnerships between medical device manufacturers, reproductive genetics companies, and fertility service providers continue to accelerate innovation.

NEW PRODUCT DEVELOPMENT

Innovation remains a defining characteristic of the Assisted Reproductive Technology (ART) Market as manufacturers introduce advanced laboratory technologies designed to improve fertilization efficiency, embryo development, and clinical outcomes. Modern time-lapse embryo monitoring systems now capture thousands of embryo images without disturbing incubation conditions, enabling continuous developmental assessment. More than 90% of newly installed embryo freezing systems utilize vitrification technology because embryo survival after thawing frequently exceeds 95%. Artificial intelligence has become increasingly integrated into embryo grading software, assisting embryologists in identifying embryos with stronger implantation potential.

New culture media formulations are designed to optimize embryo metabolism throughout different developmental stages, while automated incubators maintain highly stable environmental conditions with approximately 5% oxygen concentration. Digital witnessing systems reduce laboratory identification errors and improve procedural safety. Portable cryogenic storage systems, robotic micromanipulation equipment, high-resolution sperm analysis platforms, and cloud-based laboratory management software continue expanding product portfolios across the reproductive medicine industry.

RECENT DEVELOPMENTS

• August 2026: CooperSurgical Inc. received FDA clearance for the Wallace Aspiration Pump, designed to provide stable pressure management and consistent device behavior during oocyte retrieval, with a digital touchscreen and customizable settings supporting efficient, predictable fertility clinic procedures and workflows.

• July 2026: Vitrolife launched EmbryoCath, an embryo transfer catheter developed for safe, precise transfer, while rolling out EmbryoViewer Pro software for EmbryoScope systems, strengthening its ART portfolio with tools intended to improve clinical handling and IVF laboratory workflow efficiency globally.

• April 2026: Ferring B.V. and Gallup announced the Ferring Global Fertility Monitor, a multinational research initiative examining factors shaping fertility and family-building choices, strengthening the evidence base available to policymakers, healthcare systems, and reproductive medicine stakeholders across international healthcare markets.

• March 2025: Hamilton Thorne became part of Nexpring Health, combining its reproductive technology expertise with Cook Reproductive Health, Planer, IVFtech, Gynemed, Gynétics, Microptic, and TekEvent to create a broader fertility platform supporting IVF laboratories, clinics, and reproductive healthcare providers worldwide.

• January 2025: Irvine Scientific entered a transaction through which an affiliate of Hamilton Thorne agreed to acquire its assisted reproductive technology and cytogenetics product offerings, combining IVF media expertise with a broader reproductive-health platform serving fertility laboratories and clinics globally.

ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET REPORT COVERAGE

The Assisted Reproductive Technology (ART) Market report provides a comprehensive evaluation of global industry performance, technological developments, competitive positioning, regulatory frameworks, and future growth opportunities. The report analyzes infertility prevalence affecting approximately 17% of adults worldwide and examines more than 3 million ART treatment cycles performed annually. It includes detailed assessment of treatment types, application segments, laboratory technologies, fertility preservation, reproductive genetics, embryo culture systems, cryopreservation, and artificial intelligence integration.

The report evaluates market performance across North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting regional market shares, healthcare infrastructure, treatment accessibility, and fertility clinic expansion. Company profiling includes leading manufacturers involved in embryo culture media, laboratory equipment, imaging systems, reproductive genetics, and fertility solutions. The study further reviews technological innovations including time-lapse embryo monitoring, vitrification, digital laboratory management, automated incubators, and AI-assisted embryo selection. Investment trends, strategic partnerships, product innovation, regulatory developments, and competitive strategies are also examined to provide a complete understanding of the Assisted Reproductive Technology (ART) Market while supporting informed business planning, product development, expansion strategies, and long-term industry decision-making.